Mpm Bioventures Iv Qp Lp - Net Worth and Insider Trading

Mpm Bioventures Iv Qp Lp Net Worth

The estimated net worth of Mpm Bioventures Iv Qp Lp is at least $49 Million dollars as of 2024-11-06. Mpm Bioventures Iv Qp Lp is the of Pacira BioSciences Inc and owns about 2,790,479 shares of Pacira BioSciences Inc (PCRX) stock worth over $48 Million. Mpm Bioventures Iv Qp Lp is also the 10% Owner of Conatus Pharmaceuticals Inc and owns about 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) stock worth over $667,565. Details can be seen in Mpm Bioventures Iv Qp Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Mpm Bioventures Iv Qp Lp has not made any transactions after 2013-07-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Mpm Bioventures Iv Qp Lp

To

Mpm Bioventures Iv Qp Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mpm Bioventures Iv Qp Lp owns 6 companies in total, including Syndax Pharmaceuticals Inc (SNDX) , Chiasma Inc (CHMA) , and TriVascular Technologies Inc (TRIV) among others .

Click here to see the complete history of Mpm Bioventures Iv Qp Lp’s form 4 insider trades.

Insider Ownership Summary of Mpm Bioventures Iv Qp Lp

Ticker Comapny Transaction Date Type of Owner
SNDX Syndax Pharmaceuticals Inc 2016-03-02 10 percent owner
CHMA Chiasma Inc 2015-07-21 10 percent owner
TRIV TriVascular Technologies Inc 2014-04-22 10 percent owner
LIMIT LIMIT 2013-05-30 10 percent owner
LIMIT LIMIT 2013-07-24 10 percent owner
LIMIT LIMIT 2013-03-11 10 percent owner

Mpm Bioventures Iv Qp Lp Latest Holdings Summary

Mpm Bioventures Iv Qp Lp currently owns a total of 2 stocks. Among these stocks, Mpm Bioventures Iv Qp Lp owns 2,790,479 shares of Pacira BioSciences Inc (PCRX) as of March 11, 2013, with a value of $48 Million and a weighting of 98.63%. Mpm Bioventures Iv Qp Lp also owns 1,192,080 shares of Conatus Pharmaceuticals Inc (CNAT) as of July 30, 2013, with a value of $667,565 and a weighting of 1.37%.

Latest Holdings of Mpm Bioventures Iv Qp Lp

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PCRX Pacira BioSciences Inc 2013-03-11 2,790,479 17.28 48,219,477
CNAT Conatus Pharmaceuticals Inc 2013-07-30 1,192,080 0.56 667,565

Holding Weightings of Mpm Bioventures Iv Qp Lp


Mpm Bioventures Iv Qp Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Mpm Bioventures Iv Qp Lp has made a total of 0 transactions in Pacira BioSciences Inc (PCRX) over the past 5 years. The most-recent trade in Pacira BioSciences Inc is the sale of 500,000 shares on March 11, 2013, which brought Mpm Bioventures Iv Qp Lp around $14 Million.

According to the SEC Form 4 filings, Mpm Bioventures Iv Qp Lp has made a total of 0 transactions in Conatus Pharmaceuticals Inc (CNAT) over the past 5 years. The most-recent trade in Conatus Pharmaceuticals Inc is the acquisition of 165,265 shares on July 30, 2013, which cost Mpm Bioventures Iv Qp Lp around $2 Million.

Insider Trading History of Mpm Bioventures Iv Qp Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mpm Bioventures Iv Qp Lp Trading Performance

GuruFocus tracks the stock performance after each of Mpm Bioventures Iv Qp Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mpm Bioventures Iv Qp Lp is 24.49%. GuruFocus also compares Mpm Bioventures Iv Qp Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mpm Bioventures Iv Qp Lp within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mpm Bioventures Iv Qp Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mpm Bioventures Iv Qp Lp

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
3 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 4.56 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.04 LIMIT LIMIT LIMIT LIMIT LIMIT

Mpm Bioventures Iv Qp Lp Ownership Network

Ownership Network List of Mpm Bioventures Iv Qp Lp

No Data

Ownership Network Relation of Mpm Bioventures Iv Qp Lp

Insider Network Chart

Mpm Bioventures Iv Qp Lp Owned Company Details

What does Syndax Pharmaceuticals Inc do?

Who are the key executives at Syndax Pharmaceuticals Inc?

Mpm Bioventures Iv Qp Lp is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include Chief Financial Officer Keith A. Goldan , director & Chief Executive Officer Briggs Morrison , and President & Head of R&D Neil Gallagher .

Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary

Over the past 18 months, Mpm Bioventures Iv Qp Lp made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 211,420 shares made by Briggs Morrison , a net purchase of 673 shares made by Keith A. Goldan , and a net sale of 83,000 shares made by William Meury .

In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 294,997 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 1,250 shares were bought by its insiders, resulting in a net sale of 293,747 shares.

Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Syndax Pharmaceuticals Inc Insider Transactions

No Available Data

Mpm Bioventures Iv Qp Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Mpm Bioventures Iv Qp Lp. You might contact Mpm Bioventures Iv Qp Lp via mailing address: 200 Clarendon Street, 54th Floor, Boston Ma 02116.